A phase II trial comparing crenolanib vs. midostaurin in combination with induction chemotherapy and consolidation therapy in newly diagnosed AML patients (≤60 years) with the FLT3 mutation is ongoing (NCT03258931). The gene discussed is FLT3; the disease is acute myeloid leukemia.